Clinical Trials Logo

Filter by:
NCT ID: NCT03374085 Active, not recruiting - Multiple Myeloma Clinical Trials

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Start date: February 6, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). All eligible subjects must be previously treated with at least 3 prior regimens including lenalidomide, pomalidomide, a proteasome inhibitor and an anti-CD38 antibody and be refractory to their last line of therapy.

NCT ID: NCT03372005 Active, not recruiting - Clinical trials for Type2 Diabetes, Cardiovascular Diseases

The Effect of Floorball on Health and Performance in Subjects With Lifestyle Diseases

Start date: September 12, 2017
Phase: N/A
Study type: Interventional

To investigate the effect of floorball on health and performance in subjects with either type 2 diabetes or cardiovascular diseases.

NCT ID: NCT03371238 Active, not recruiting - Aging Problems Clinical Trials

Effect of Floorball on Healthy Subjects

Start date: September 14, 2017
Phase: N/A
Study type: Interventional

To investigate the effect of floorball on health and performance in healthy subjects over 65 years.

NCT ID: NCT03358589 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

Molecular Evaluation in Metastatic Breast Cancer

MESTAR
Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Background: Despite that up 90% of patients with early-stage breast cancer receives adjuvant treatment, there are still about 300 patients diagnosed with primary metastatic breast cancer (MBC) and about 1,200 patients who develop metastases after the primary treatment each year in Denmark. Aim: The investigators hypothesize that molecular evaluation with FDG-PET/CT and diffusion weighted MRI allows an earlier detection of failure to respond to potentially toxic drugs in patients receiving breast cancer directed treatments. The aims of our project are to address the following questions: - Does FDG-PET/CT allow an earlier detection of failure to respond to treatment for MBC than conventional CT? - Does FDG-PET/CT or MRI allow an earlier detection of failure to respond to treatment for bone metastatic disease than conventional CT? - Does the PET based criteria (PERCIST) have the potential to lead to changes in the treatment plans made from CT based criteria (RECIST)? - Does FDG-PET/CT give a more accurate diagnosis of MBC than conventional CT in terms of number and distribution of metastatic sites? Method: Part A - the accuracy study: The study population will comprise all women referred to Odense University Hospital with suspected metastatic breast cancer (MBC). The investigators expect to include 270 patients who will be examined with FDG-PET/CT. If bone metastases are detected, the patients will proceed to MRI. All patients with suspected metastases on FDG-PET/CT or MRI will have a biopsy from a suitable lesion Part B - the response evaluation study: The investigators expect to include 90 patients with biopsy-verified MBC. Patients will receive oncologic treatment according to national guidelines. Response to treatment will be evaluated by conventional CT criteria and compared to novel criteria according to FDG- PET/CT, and MRI. Test results will be blinded to each other, so that knowledge of other test results will be unknown for the reader of the CT, FDG-PET/CT or MRI, respectively Expected clinical impact: This project represents a truly multidisciplinary effort to improve the diagnosis, staging, and response evaluation of MBC. The investigators hope that patients will benefit in terms of being spared for ineffective toxic treatment due to earlier detection of failure to respond, and hence leading to earlier treatment transition. Patients are involved in the planning and conduct of the project.

NCT ID: NCT03355209 Active, not recruiting - Clinical trials for Lennox Gastaut Syndrome

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

Start date: November 27, 2017
Phase: Phase 3
Study type: Interventional

This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS).

NCT ID: NCT03353831 Active, not recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Start date: September 11, 2018
Phase: Phase 3
Study type: Interventional

This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum based chemotherapy or 3rd relapse.

NCT ID: NCT03353818 Active, not recruiting - Type2 Diabetes Clinical Trials

Golf and Diabetes.

Start date: May 1, 2017
Phase: N/A
Study type: Interventional

This a randomised, single-blinded, controlled study that investigate if a free golf training programme will increase the physical activity of type 2 diabetes patients.

NCT ID: NCT03349801 Active, not recruiting - Clinical trials for Age Related Macular Degeneration (AMD)

Development of Novel Clinical Endpoints in Intermediate AMD

MACUSTAR
Start date: March 26, 2018
Phase:
Study type: Observational

Development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention in patients with intermediate age-related macular degeneration (AMD) - MACUSTAR

NCT ID: NCT03348969 Active, not recruiting - Bladder Cancer Clinical Trials

Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC

NICSA
Start date: November 1, 2017
Phase: Phase 4
Study type: Interventional

A randomized controlled trial aiming to investigate neoadjuvant, short-term intensive chemoresection with Mitomycin C compared to standard treatment with TURB and adjuvant intravesical instillation therapy in patients with recurrent non-muscle invasive bladder cancer (NMIBC).

NCT ID: NCT03347162 Active, not recruiting - Cancer Clinical Trials

Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer

Start date: December 1, 2017
Phase:
Study type: Observational

PURPOSE: To determine the prognostic properties of a comprehensive evaluation of body composition and physical function in patients with GI-HEP cancer from point of diagnosis and throughout the treatment trajectory. GI-HEP: Patients with tumors of the upper gastrointestinal or hepatobiliary tract, specifically tumors of the esophagus, gastro-esophageal junction, stomach, primary tumors of the liver or biliary tract, as well as colorectal liver metastasis or tumors of the pancreas.